Proposal to fund nitisinone for people with rare inherited metabolic disorders

We want your feedback on a proposal to fund nitisinone for people with rare inherited metabolic disorders, including tyrosinemia type 1 and alkaptonuria.

Nitisinone is currently funded through Pharmac’s Named Patient Pharmaceutical Assessment (NPPA) pathway. Under this proposal, it would be listed on the Pharmaceutical Schedule, making it easier for clinicians to prescribe and helping ensure ongoing supply in New Zealand.

More information about the proposal is available here

The consultation webpage includes an online form for you to provide feedback. Consultation closes 5pm 12 December 2025.

If the proposal is approved, the funding change would start from 1 February 2026.

Ngā mihi,

Josh Wiles (he/him) | Senior Therapeutic Group Manager/Team Leader 

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz